Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

BACKGROUND: We previously reported the good feasibility and favorable efficacy of perioperative capecitabine plus oxaliplatin (CapeOx) in patients (pts) with clinical T3(SS)/T4a(SE) N1-3 M0 gastric cancer (GC) in a phase II study in which the pathological response rate, the primary endpoint, of 54.1...

Full description

Bibliographic Details
Main Authors: Akamaru, Y. (Author), Endo, S. (Author), Fujita, S. (Author), Fujitani, K. (Author), Goto, M. (Author), Imano, M. (Author), Kato, T. (Author), Kawabata, R. (Author), Kawakami, H. (Author), Kurokawa, Y. (Author), Lee, S.-W (Author), Matsuyama, J. (Author), Sakai, D. (Author), Satoh, T. (Author), Shimokawa, T. (Author), Taniguchi, H. (Author), Tatsumi, M. (Author), Terazawa, T. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
capecitabine
Capecitabine
clinical trial
gastrectomy
Gastrectomy
gastric cancer
human
Humans
Neoplasm Recurrence, Local
oxaliplatin
Oxaliplatin
pathology
perioperative chemotherapy
phase 2 clinical trial
Stomach Neoplasms
stomach tumor
tumor recurrence
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items